AGN -3% on TEVA selloff. AGN owns ~100M TEVA shares from the 2016 sale of the Acatavis generic-drug business (#msg-124264340). Why didn’t AGN sell these shares sooner? Ask Brent Saunders.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”